Description
SCO-267 is a novel GPR40 full agonist, improving liver parameters in a mouse model of nonalcoholic fatty liver disease without affecting glucose or body weight.
Uses
SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1].
in vivo
SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1].
| Animal Model: | N-STZ rats[1] |
| Dosage: | 1 or 10 mg/kg |
| Administration: | P.o.; |
| Result: | Improved insulin sensitivity and exerted sustained glucose-lowering effect.
|
References
[1] Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293. DOI:
10.1124/molpharm.120.000168
